Opyt ispol'zovaniya inkretinomimetikov v lechenii bol'nykh sakharnym diabetom tipa 2


Cite item

Full Text

Abstract

Современная стратегия в терапии сахарного диабета (СД) типа 2 (СД2) предполагает коррекцию хронической гликемии за счет преодоления инсулинорезистентности и улучшения β-клеточной функции поджелудочной железы. В последнее время в качестве секретогенов инсулина при комбинированной терапии СД часто используют инкретиномиметики [1, 3]. Такая терапевтическая тактика имеет патофизиологическую основу. Регуляция гомеостаза глюкозы в организме осуществляется сложной мультигормональной системой, включающей гормоны не только поджелудочной железы, но и гормоны-инкретины, вырабатываемые в кишечнике в ответ на прием пищи. «Эффект инкретина», или стимуляция секреции инсулина после перорального приема углеводов посредством гормонов-инкретинов, свидетельствует о большой значимости сигналов желудочно-кишечного тракта в гормональной регуляции гомеостаза глюкозы [25]. Данные, указывающие на дефицит инкретинов при СД 2, являются основанием для того, чтобы считать препараты, усиливающие инкреторный эффект, новым терапевтическим принципом в лечении диабета [2]. Это обстоятельство диктует необходимость создания новых препаратов на основе использования эффектов гормонов-инкретинов, позволяющих не только устранять метаболические нарушения, но и сохранять функциональную активность клеток поджелудочной железы, стимулируя и активизируя физиологические механизмы регуляции секреции инсулина и содержания глюкозы крови.

About the authors

A. S Ametov

РМАПО, Москва

Кафедра эндокринологии и диабетологии

E. N Pakus

РМАПО, Москва

Кафедра эндокринологии и диабетологии

References

  1. Аметов А.С., Солуянова Т.Н. Современные подходы к комбинированному лечению сахарного диабета 2-го типа. Cons. Med. 2007; 9 (9): 16–23.
  2. Анциферов М.Б., Дорофеева Л.Г. Инкретиномиметики в терапии сахарного диабета 2-го типа. Леч. врач 2009; 3: 12–7.
  3. Викулова О.К., Шестакова М.В. Клиническая эффективность миметика инкретинов экзенатида: результаты исследований и показания к применению у больных сахарным диабетом типа 2. Cons. Med. 2008; 10 (9).
  4. Abdul-Ghani M.A, Defronzo R.A. Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes. Diabetes Care 2009; 32 (2): 5194–8.
  5. Amori R.E, Lau J, Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes. Systemic review and meta - analysis. JAMA 2007; 298): 194–206.
  6. Apovian C.M, Bergenstal R.M, Cuddihy R.V et al. Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes. Am J Med 2010; 123 (5): 9–17.
  7. Barnett A, Ausworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007; 23: 1493–507.
  8. Bunck M.C, Diamant M.D, Corner A, Elliasson B et al. One - Year Treatment With Exenatide Improves - Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. Diabetes Care 2009; 32 (5): 762–8.
  9. Buse J, Henry R, Han J. Effests of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea - treated patients with type 2 diabetes. Diabetes Care 2004; 27 (11): 2628–35.
  10. Christensen M, Knop F.C. Once - Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide? Curr Diab Rep 2010; 10: 124–32.
  11. Davis S.N, Johns D, Maggs D. Exploring the substitution of exenatide for insulin in patients treated with insulin in combination with oral antidiabetes agents. Diabet Care 2007; 30: 2767–72.
  12. De Fronzo R, Ratner R, Han J. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin - treated patients with type 2 diabetes. Diabet Care 2005; 28 (5): 1092–100.
  13. Degn K.B, Brock B, Juhl C.B. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose - dependent insulin secretion and couter - regularion during hypoglycemia. Diabetes 2004; 53 (9): 2397–403.
  14. Edwards C.M.B, Stanley S.A, Davis R. Exendin-4 reduses fasting and postprandial glucose decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281 (1): E155–161.
  15. Egоn J.M, Clocquet A.R, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87 (3): 1282–90.
  16. Fehse F.C, Trautmann M.E, Hoist J.J, Halseth A.E. Exenatide augments first - and second - phase insulin secretion in response to intravenous glucose in subjects with type 2 diobetes. J Clin Endocrinol Metob 2005; 90: 5991–7.
  17. Finemon M.S, Bicsak Т.А, Shen L.Z. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diobetes. Diabetes Care 2003; 26 (8): 2370–7.
  18. Heine R.J, Van Gaal L.F, Johns D. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143 (8): 559–69.
  19. Holz G.G. Epac: a new cAMP - binding protein in support of glucagon - like peptide-1 receptor - mediated signal transduction in the pancreatic beta - cell. Diabetes 2004; 53: 5–13.
  20. Improvement in Beta - Cell Function Observed After Three Years of BYETTAR (exenatide) Injection Therapy: Data Presented at ADA 2010. Study Showed Improvements Compared to Insulin Glargine. Copyright American Diabetes Association. Inc. June 26, 2010. Presentation p. 728.
  21. Kendall D.M, Riddle M.C, Rosenstock J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28 (5): 1083–91.
  22. Kim D, Mac Conell L, Zhuang D. Effects of once - weekly dosing of a long - acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487–93.
  23. Kolterman O.G, Buse J.B, Fineman M.S. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082–9.
  24. Moretto T.J, Milton D.R, Ridge T.D et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug - naive patients with type 2 diabetes: a randomized, double - blind, placebo - controlled, parallel - group study. Clin Ther 2008; 30: 1448–60.
  25. Mortensen K, Christensen L.L, Holst J.J, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Rept 2003; 114: 189–96.
  26. Nauck M.A, Heimesaat M.M, Orskov C et al. Preserved incretin activity of glucagon - like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301–7.
  27. Nauck M.A, Duran S, Kim D. A comparison of a twice - daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non - inferiority study. Diabetologia 2007; 50: 259–67.
  28. Nelson P, Poon T, Guan X et al. The incretinmimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes technology & therapeutics. 2007; 9: 317–26.
  29. Poon T, Nelson P, Shen L. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose - ranging study. Diabetes Technol Ther 2005; 7 (3): 467–77.
  30. Ratner R.E., Maggs D, Nielsen L.L, Stonehouse A.H. Long term effects of exenatide therapy over 82 weeks on glycemic control ond weight in over - weigt mefformin - treored patients with type 2 diabetes mellitus. Diabetes Obes Metob 2006; 11: 233–8.
  31. Shah P, Velio А, Rizza R.A. Glucagon physiology, pathophysiology ond prospects of glucagons antagonists for the treatment of diabetes. Diabetes Monitor 2005; 17 (61): 3–10.
  32. Vilsboll T, Krarup T, Madsbad S, Hoist J.J. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111–9.
  33. Wajchenberg B.L. β - Cell failure in diabetes and preservation by clinical treatment. Endocrine Rev 2007; 28 (2): 187–218.
  34. Xu G, Staffers D.A, Habener J.F, Bonner-Weir S. Exendin-4 stimulates both beta - cell replication and neogenesis, resulting in increased beta - cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270–6.
  35. Zander M, Madsbad S, Madsen J.L, Hoist J.J. Effect of 6-week course of glucagon - like peptide 1 on glycaemic control, insulin sensitivity, and beta - ceil function in type 2 diabetes: a parallel - group study. Lancet 2002; 359: 824–30.
  36. Zinman B, Hoogwerf B.J, Garcia S.D. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007; 146: 477–85.

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies